Skip to main content
ARS Home » Research » Publications at this Location » Publication #151745


item Grubman, Marvin

Submitted to: Meeting Abstract
Publication Type: Proceedings
Publication Acceptance Date: 3/17/2003
Publication Date: N/A
Citation: N/A

Interpretive Summary:

Technical Abstract: The recent outbreaks of foot-and-mouth disease (FMD) in previously disease-free countries have demonstrated that FMD-free countries are vulnerable to disease incursion. The current vaccine an inactivated whole virus preparation has a number drawbacks when used during outbreaks in disease-free countries. We have developed a combination control strategy including a new subunit vaccine and an antiviral agent to address these concerns. New generation vaccines utilizing an FMD virus (FMDV) empty viral capsid subunit delivered to animals by a live recombinant replication-defective human adenovirus (Ad5) vector have been developed. Swine vaccinated with one dose of this recombinant Ad5 and challenged one, two, or six weeks later with virulent animal-passaged homologous virus are protected from clinical signs of FMD as well as from replication of the challenge virus. Administration of an Ad5 vector containing a porcine type I interferon (IFN) gene induces protection in swine challenged one day later with virulent FMDV. Furthermore, a combination of this antiviral treatment and the empty capsid subunit vaccine protects swine challenged five days later and presumably up to at least 6 weeks. In preliminary studies in cattle, we have shown that administration of Ad5-IFN delays and reduces the severity of disease in animals challenged one or two days later.